Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety [0.03%]
生物类似药与生物类似药转换对疗效和安全性影响的研究
Anan S Jarab,Shrouq R Abu Heshmeh,Ahmad Z Al Meslamani
Anan S Jarab
Michelle Greenman,Blair McNamara,Levent Mutlu et al.
Michelle Greenman et al.
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics [0.03%]
驯服野兽：基于抗体的细胞因子拟态的工程策略及生物医学潜能
Lukas Pekar,Simon Krah,Stefan Zielonka
Lukas Pekar
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups [0.03%]
成人血脂异常的单克隆抗体：重点关注脆弱患者群体
Na-Qiong Wu,Zhi-Fan Li,Meng-Ying Lu et al.
Na-Qiong Wu et al.
Introduction: Dyslipidemia significantly contributes to atherosclerotic cardiovascular disease (ASCVD). Patients with lipid-rich vulnerable plaques are particularly susceptible to cardiovascular complications. Despite ava...
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males [0.03%]
CT-P41（一种denosumab生物类似药）与参考denosumab在健康男性中的随机、双盲、单剂量、一期研究：对比药代动力学、药效动力学、安全性和免疫原性
Anhye Kim,Jang Hee Hong,Wonsuk Shin et al.
Anhye Kim et al.
Background: This study's objective was to demonstrate pharmacokinetic (PK) similarity and safety of denosumab biosimilar, CT‑P41, and United States-licensed reference denosumab (US-denosumab) in healthy male Asian adults...
Stefano Molica,Marco Rossi,David Allsup
Stefano Molica
Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies [0.03%]
成人克罗恩病生物制剂的临床应用：来自真实世界研究的启示
Antonio Tursi,Giammarco Mocci,Angelo Del Gaudio et al.
Antonio Tursi et al.
Introduction: The therapeutic armamentarium for managing Crohn's disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor (TNF)-α,...
Cecil Nick
Cecil Nick
Introduction: Biosimilar clinical programs could be streamlined by prudent application of improved methodologies and knowledge accumulated over the past 20 years. This review focuses on whether complex comparative efficac...
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas [0.03%]
Glofitamab的评估：作为复发或难治性大B细胞淋巴瘤的首个固定疗程双特异性抗体
Kamila Polgarova,Marek Trneny
Kamila Polgarova
Introduction: Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies mainly ba...
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside [0.03%]
慢性病毒性肝炎的治疗：CD8+T细胞从实验室到临床VRTX
Julia Lang-Meli,Christoph Neumann-Haefelin,Robert Thimme
Julia Lang-Meli
Introduction: More than 350 million people worldwide live with chronic viral hepatitis and are thus at risk for severe complications like liver cirrhosis and hepatocellular carcinoma (HCC). To meet the goals of the World ...